Investigational Studies

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

Epidiolex ist eine Cannabidiol-Lösung zum Einnehmen bei Patienten mit LGS, einer seltenen, schweren Form der Epilepsie, die im Kindesalter beginnt und schwierig zu behandeln ist. Aber auch beim Dravet-Syndrom soll das Arzneimittel zur Anwendung kommen. Der Hersteller GW hatte die Zulassung im Januar beantragt. „Wir befinden uns derzeit in der letzten Überprüfungsphase des Arzneimittelzulassungsantrags für […]

– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – – Both doses significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic drugs – LONDON and CARLSBAD, Calif., May 16, […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

– Positive unanimous vote at Epidiolex® (cannabidiol) FDA Advisory Committee meeting –– NDA PDUFA goal date scheduled for June 27, 2018 –– Conference call today at 4:30 p.m. EST – LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on […]

On this auspicious April 20th, three developments in the world of cannabis regulation caught our attention. The first is the unanimous recommendation by a panel of outside advisers to FDA in favor of approving Epidiolex, an epilepsy drug manufactured by GW Pharmaceuticals. The active ingredient in Epidiolex is cannabidiol (CBD), which is a chemical found […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]